### ****NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID)****

##### [NIAID COVID-19 research priorities](https://www.nih.gov/news-events/news-releases/niaid-strategic-plan-details-covid-19-research-priorities)

##### [Notice of Special Interest: Emergency Competitive Revisions for Research on SARS-CoV-2 and COVID-19](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html)

* **Due:**Rolling until March 25, 2021
* **Funding:**Not more than annual amount of current parent award
* **Project period:** 2 years
* **Purpose:** To focus research on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

##### [Notice of Special Interest: SARS-CoV-2 & COVID-19](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html)

* **Due:** Rolling until April 5, 2021
* **Funding:** Varies by FOA
* **Project period:** Varies by FOA
* **Purpose:**To focus on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

##### [Partnerships for Countermeasures against Select Pathogens (R01 clinical trials not allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html)

* **Due:**June 29, 2020
* **Funding:**$750,000 per year; additional $300,000 can be requested in year 1
* **Project period:** Up to 5 years
* **Purpose:** To support milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

### ****DEPARTMENT OF DEFENSE****

##### [Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)](https://www.grants.gov/web/grants/search-grants.html?keywords=W81XWH-20-PRMRP-TTDA-COV)

* **Letter of intent due:** May 28, 2020
* **Application due:** June 12, 2020
* **Funding:**Maximum of $4.0 M direct costs
* **Project period:** 4 years
* **Purpose:**To provide support for the translation of promising preclinical findings into products for clinical applications.